Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease

• Autores: Arriola-Montenegro, Jose, Beas, Renato, Cerna-Viacava, Renato, Chaponan-Lavalle, Andres, Hernandez Randich, Karla, Chambergo-Michilot, Diego, Flores Sanga, Herson, Mutirangura, Pornthira
• Formato: artículo
• Fecha de Publicación: 2023
• Institución: Universidad Peruana de Ciencias Aplicadas
• Repositorio: UPC-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorioacademico.upc.edu.pe:10757/669048
• Enlace del recurso: http://hdl.handle.net/10757/669048
• Nivel de acceso: acceso abierto
• Materia: Cardiovascular disease; Heart Failure; Heart failure reduced ejection fraction; Non-alcoholic fatty liver disease; Novel therapies; HFrEF (Heart Failure with Reduced Ejection Fraction); NAFLD (Nonalcoholic Fatty Liver Disease); Comorbidities; Targeted Therapies; Angiotensin-Converting Enzyme Inhibitors (ACEi); Angiotensin Receptor Blockers (ARBs); Mineralocorticoid Receptor Antagonist; Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i); Multidisciplinary Approach; Novel Therapies

Heart failure with reduced ejection fraction (HFrEF) and nonalcoholic fatty liver disease (NAFLD) are two common comorbidities that share similar pathophysiological mechanisms. There is a growing interest in the potential of targeted therapies to improve outcomes in patients with coexisting HFrEF and NAFLD. This manuscript reviews current and potential therapies for patients with coexisting HFrEF and NAFLD. Pharmacological therapies, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoids receptor antagonist, and sodium-glucose cotransporter-2 inhibitors, have been shown to reduce fibrosis and fat deposits in the liver. However, there are currently no data showing the beneficial effects of sacubitril/valsartan, ivabradine, hydralazine, isosorbide nitrates, digoxin, or beta blockers on NAFLD in patients with HFrEF. This study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these comorbidities. Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.